Your browser doesn't support javascript.
loading
Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
Bazzi, Angela R; Bordeu, Michelle; Baumgartner, Katrina; Sproesser, Darien M; Bositis, Christopher M; Krakower, Douglas S; Mimiaga, Matthew J; Biello, Katie B.
Afiliación
  • Bazzi AR; Herbert Wertheim School of Public Health, University of California, 9500 Gilman Drive, San Diego, La Jolla, 92093, CA, USA. abazzi@health.ucsd.edu.
  • Bordeu M; Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA. abazzi@health.ucsd.edu.
  • Baumgartner K; Herbert Wertheim School of Public Health, University of California, 9500 Gilman Drive, MTF 265E (Mail Code 0725), La Jolla, 92161, CA, USA. abazzi@health.ucsd.edu.
  • Sproesser DM; Fenway Health, Boston, MA, USA.
  • Bositis CM; Greater Lawrence Family Health Center, Lawrence, MA, USA.
  • Krakower DS; Fenway Health, Boston, MA, USA.
  • Mimiaga MJ; Greater Lawrence Family Health Center, Lawrence, MA, USA.
  • Biello KB; Department of Family and Community Medicine, University of California, San Francisco, USA.
BMC Public Health ; 23(1): 513, 2023 03 17.
Article en En | MEDLINE | ID: mdl-36932369
BACKGROUND: HIV incidence has recently increased among people who inject drugs (PWID) across the United States, with outbreaks occurring in states with long-standing syringe service programs (SSPs) including Massachusetts (MA). Antiretroviral pre-exposure prophylaxis (PrEP) is an evidence-based HIV prevention strategy recommended for PWID, but uptake in this marginalized population is extraordinarily low. METHODS: We describe the design and procedures for a National Institute on Drug Abuse (NIDA)-funded (R01) randomized controlled trial (RCT) testing the efficacy of "PrEP for Health," a multicomponent behavioral intervention to increase PrEP uptake, adherence, and persistence among HIV-negative PWID attending SSPs in two areas of the U.S. Northeast that are heavily affected by injection-related HIV transmission. Participants are equally randomized to receive the "PrEP for Health" intervention (involving individually tailored HIV and PrEP education, motivational interviewing, problem-solving skills and planning, and ongoing navigation support) or an enhanced standard of care (eSOC) control condition involving a brief educational video on the utility of PrEP for HIV prevention. Co-primary outcomes are PrEP uptake (using medical/pharmacy records) and adherence (using tenofovir quantification in hair samples); a secondary outcome is PrEP persistence (using medical/pharmacy records) over 12 months. Major assessments occur at baseline, 1-, 3-, 6-, and 12-month follow-up visits. Planned analyses will examine intervention efficacy, specific hypothesized conceptual mediators of the intervention effect (e.g., self-perceived HIV risk; PrEP knowledge, interest in use, motivation, and behavioral skills) and epidemiologically linked moderators (e.g., age; gender; condomless vaginal or anal sex). DISCUSSION: Findings from our extensive preliminary research with the study population revealed that a multicomponent, theory-based intervention targeting PrEP knowledge, motivation, self-efficacy, behavioral skills, and structural barriers to PrEP access is urgently needed for PWID who are at risk of HIV acquisition. We also learned that SSPs represent a highly acceptable service setting for delivering such interventions. In this study, we are evaluating the efficacy of the "PrEP for Health" intervention. If efficacious, findings from our implementation evaluation could help guide its dissemination to diverse SSPs and possibly other community-based settings accessed by this population. TRIAL REGISTRATION: ClinicalTrials.gov number NCT04430257, registered June 12, 2020.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_enfermedades_transmissibles / 2_sustancias_psicoativas Asunto principal: Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / Fármacos Anti-VIH / Consumidores de Drogas / Profilaxis Pre-Exposición Tipo de estudio: Clinical_trials / Qualitative_research Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_enfermedades_transmissibles / 2_sustancias_psicoativas Asunto principal: Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / Fármacos Anti-VIH / Consumidores de Drogas / Profilaxis Pre-Exposición Tipo de estudio: Clinical_trials / Qualitative_research Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
...